tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Moleculin Biotech Secures European Patent for Annamycin

Story Highlights
  • Moleculin Biotech received a Notice of Intent to Grant for a European patent for Annamycin.
  • The patent strengthens Moleculin’s market position in Europe and validates Annamycin’s potential.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Moleculin Biotech Secures European Patent for Annamycin

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Moleculin Biotech ( (MBRX) ).

On July 30, 2025, Moleculin Biotech announced it received a Notice of Intent to Grant for a European patent application related to its drug candidate Annamycin. This patent is expected to solidify the company’s exclusivity in the European Union for Annamycin, which is being developed as a non-cardiotoxic anthracycline for treating AML and soft tissue sarcoma lung metastases. The patent, once granted, will cover methods of making a preliposomal Annamycin lyophilizate with improved stability and high purity, potentially extending until 2040. This development enhances Moleculin’s market position in Europe and validates Annamycin’s potential as a transformative therapeutic candidate.

The most recent analyst rating on (MBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.

Spark’s Take on MBRX Stock

According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.

Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.

To see Spark’s full report on MBRX stock, click here.

More about Moleculin Biotech

Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. The company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance and cardiotoxicity, currently in development for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.

Average Trading Volume: 5,244,330

Technical Sentiment Signal: Sell

Current Market Cap: $16.62M

For an in-depth examination of MBRX stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1